Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF)

What Was Tested

Researchers studied Goserelin in this randomized controlled trial publication.

The purpose of this study was to compare changes in bone mineral density (BMD) in premenopausal patients with node-positive early breast cancer treated with goserelin (Zoladex) or cyclophosphamide, methotrexate and 5-fluorouracil (CMF).

Why It Was Studied

At 3 years, partial recovery of BMD was observed in goserelin recipients.

In contrast, mean BMD losses for the CMF group indicated persistent BMD loss.

Who Took Part

The abstract describes 96 patients taking part.

The age groups tagged for this paper are adults, women only.

In a protocoled sub-study involving 96 patients from eight centers (goserelin: n=53; CMF: n=43), lumbar spine (L2-L4) and femoral neck BMD were assessed by dual X-ray absorptiometry at baseline and then annually for 3 years.

How the Study Was Run

The researchers set it up as a randomized study.

The patients were allocated by chance, so the Goserelin group and the comparison group should start out alike.

The methods mention a period of 3 years.

What Was Measured

PubMed files the paper under topics including Amenorrhea, Antineoplastic Agents, Hormonal, Antineoplastic Combined Chemotherapy Protocols, Bone Density, Breast Neoplasms, Cyclophosphamide and Femur Neck.

What This Means in Plain Language

The paper is a randomized study of Goserelin in 96 patients over 3 years.

The publication is from 2003 (Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA), a journal based in England.

More context: the Goserelin compound page, all human trials.